Teva presents latest schizophrenia treatment research, including phase 3 SOLARIS trial results
- Teva presented findings from the Phase 3 SOLARIS trial at Psych Congress 2024, showing TEV-'749 improved social functioning and quality of life in adults with schizophrenia.
- TEV-'749, a subcutaneous long-acting injectable, showed no Post-Injection Delirium/Sedation Syndrome (PDSS) events and maintained a consistent safety profile.
- Real-world analyses of UZEDY (risperidone) revealed high adherence rates among adults with schizophrenia facing treatment barriers.
- The SOLARIS study is an 8-week, randomized, double-blind, placebo-controlled trial, followed by a 48-week open-label safety period.
Read more
KFSHRC and Lilly collaborate in Alzheimer’s early detection
- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU to enhance Alzheimer's patient care.
- The collaboration aims to transform KFSHRC’s Neuroscience Centre into a regional hub for Alzheimer's Disease.
- Lilly will transfer manufacturing know-how for PET imaging agents to KFSHRC, enabling local production with export potential.
- The initiative includes educating Saudi healthcare professionals on neurodegenerative diseases and global best practices.
Read more
